Company: BDRX
Filing Date: 2025-01-08
Form Type: 424B3
Source: 0001214659-25-000303
Chunk: 5

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-08
Form: 424B3
Chunk 5
---
6-K is filed, to the extent not superseded by documents or reports subsequently filed or furnished.

<div align='center'>EXPLANATORY NOTE</div>

Issuance of Promissory Note

On December 23, 2024 (the “Issuance Date”),
Biodexa Pharmaceuticals PLC (the “Company”), issued a promissory note to C/M Capital Master Fund, LP (the “Holder”)
in the aggregate principal amount of $600,000 (the “Note”) at a 10% original issue discount. The Note is an unsecured obligation
of the Company and bears interest at an annual rate of 5%, which may be increased under certain circumstances, and has a maturity date
of one year from the Issuance Date. The Note includes a monthly repayment schedule, with the entire principal amount of the Note, plus
accrued and unpaid interest, due and payable by the Company on the date that is twelve (12) months from the Issuance Date (the “Maturity
Date”). The Note may be prepaid prior to the Maturity Date without penalty. Additionally, prior to the Maturity Date and while the
Note remains outstanding, upon the occurrence of each and every bona fide transaction or series of transactions conducted by the Company
wherein the principal purpose of the Company is to raise capital, pursuant to which the Company issues and sells securities for an amount
of gross proceeds equal to or greater than $500,000 (each, a “Financing Event”), the Company shall be obligated to utilize
25% of the gross proceeds from such Financing Event to prepay the Note, which repayment shall be due concurrently or immediately following
the closing of such Financing Event.

The Note contains customary representations and
warranties by the Company, and provides for certain customary events of default. Generally, if an event of default occurs and is continuing
under the Note, the Holder may require the Company to repay all amount due under the Note, including accrued and unpaid interest, immediately.

The Company received the $540,000 pursuant
to the Note on December 24, 2024.

The foregoing description of the Note does not
purport to be complete and is qualified in its entirety by the full text of the Note, which is attached hereto as Exhibit 10.1 and is
incorporated herein by reference.

New Articles of Association

As previously disclosed, on November 22, 2024,
at a general meeting the Company’s shareholders